Company
CORE Biomedicine, Inc.
Rewiring the future of oncology by targeting core lineage dependencies.
Also known as CORE Biomedicine
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
CORE Biomedicine is a preclinical-stage oncology company dedicated to innovating precision medicine therapeutics by targeting core lineage-dependent pathways in cancer.
Funding snapshot
- Total raised
- $21MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $21M2026-07-28
Funding rounds
- Series A
- $21M2026-07-28, Company stated
Loading relationship preview